G. Wakefield

Single subcutaneous doses of a luteinizing hormone-releasing hormone antagonist suppress serum gonadotropin and testosterone levels in normal men.

W. Vale, J. Rivier, C. Debold, 1986, The Journal of clinical endocrinology and metabolism.

Gonadotropins and testosterone escape from suppression during prolonged luteinizing hormone-releasing hormone antagonist administration in normal men.

W. Vale, J. Rivier, S. Pavlou, 1987, The Journal of clinical endocrinology and metabolism.

Suppression of pituitary-gonadal function by a potent new luteinizing hormone-releasing hormone antagonist in normal men.

S. Pavlou, W. Kovacs, D. Island, 1987, The Journal of clinical endocrinology and metabolism.

Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men.

J. Lindner, W. Vale, J. Rivier, 1989, The Journal of clinical endocrinology and metabolism.

Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial

C. Hellerqvist, H. Sundell, G. Thurman, 2005, Journal of Cancer Research and Clinical Oncology.

Maintenance of the ratio of bioactive to immunoreactive follicle-stimulating hormone in normal men during chronic luteinizing hormone-releasing hormone agonist administration.

J. Lindner, W. Vale, J. Rivier, 1988, The Journal of clinical endocrinology and metabolism.

Heterogeneity of sperm density profiles following 16-week therapy with continuous infusion of high-dose LHRH analog plus testosterone.

W. Vale, J. Rivier, S. Pavlou, 1986, Journal of andrology.

Phase I study of the antineovascularization drug CM101.

C. Hellerqvist, D. Johnson, H. Sundell, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

LHRH Antagonists in Normal Men

S. Pavlou, W. Kovacs, G. Wakefield, 1987 .